{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:14:51Z","timestamp":1790018091513,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Orthopedic Osteoporosis Innovation Fund of the China Medicine Education Association","award":["[2022]067"],"award-info":[{"award-number":["[2022]067"]}]},{"name":"Orthopedic Osteoporosis Innovation Fund of the China Medicine Education Association","award":["[2022]067"],"award-info":[{"award-number":["[2022]067"]}]},{"name":"Orthopedic Osteoporosis Innovation Fund of the China Medicine Education Association","award":["[2022]067"],"award-info":[{"award-number":["[2022]067"]}]},{"name":"Orthopedic Osteoporosis Innovation Fund of the China Medicine Education Association","award":["[2022]067"],"award-info":[{"award-number":["[2022]067"]}]},{"name":"Orthopedic Osteoporosis Innovation Fund of the China Medicine Education Association","award":["[2022]067"],"award-info":[{"award-number":["[2022]067"]}]},{"name":"Orthopedic Osteoporosis Innovation Fund of the China Medicine Education Association","award":["[2022]067"],"award-info":[{"award-number":["[2022]067"]}]},{"name":"Orthopedic Osteoporosis Innovation Fund of the China Medicine Education Association","award":["[2022]067"],"award-info":[{"award-number":["[2022]067"]}]},{"name":"Orthopedic Osteoporosis Innovation Fund of the China Medicine Education Association","award":["[2022]067"],"award-info":[{"award-number":["[2022]067"]}]},{"name":"Orthopedic Osteoporosis Innovation Fund of the China Medicine Education Association","award":["[2022]067"],"award-info":[{"award-number":["[2022]067"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-19835-5","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T11:27:49Z","timestamp":1763551669000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of the efficacy and safety of denosumab in the treatment of patients with osteoporotic vertebral compression fractures after PVP"],"prefix":"10.1038","volume":"15","author":[{"given":"Yixuan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenHua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengyang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"19835_CR1","doi-asserted-by":"publisher","first-page":"8863","DOI":"10.2147\/ijgm.S334972","volume":"14","author":"P Niu","year":"2021","unstructured":"Niu, P. et al. Association between HDL-C and bone mineral density: an Cross-Sectional analysis. Int. J. Gen. Med. 14, 8863\u20138872. https:\/\/doi.org\/10.2147\/ijgm.S334972 (2021).","journal-title":"Int. J. Gen. Med."},{"key":"19835_CR2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/17446651.2020.1772051","volume":"15","author":"I Chiodini","year":"2020","unstructured":"Chiodini, I., Falchetti, A., Merlotti, D., Eller Vainicher, C. & Gennari, L. Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis. Expert Rev. Endocrinol. Metabolism. 15, 283\u2013298. https:\/\/doi.org\/10.1080\/17446651.2020.1772051 (2020).","journal-title":"Expert Rev. Endocrinol. Metabolism"},{"key":"19835_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/ijms23031376","volume":"23","author":"CH Cheng","year":"2022","unstructured":"Cheng, C. H., Chen, L. R. & Chen, K. H. Osteoporosis due to hormone imbalance: an overview of the effects of Estrogen deficiency and glucocorticoid overuse on bone turnover. Int. J. Mol. Sci. 23, 17. https:\/\/doi.org\/10.3390\/ijms23031376 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"19835_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamanetworkopen.2023.54734","volume":"7","author":"HK Huang","year":"2024","unstructured":"Huang, H. K. et al. Denosumab and the risk of diabetes in patients treated for osteoporosis. JAMA Netw. Open. 7, 13. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.54734 (2024).","journal-title":"JAMA Netw. Open."},{"key":"19835_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41413-024-00362-4","volume":"12","author":"BM El-Masri","year":"2024","unstructured":"El-Masri, B. M. et al. Mapping RANKL- and OPG-expressing cells in bone tissue: the bone surface cells as activators of osteoclastogenesis and promoters of the denosumab rebound effect. Bone Res. 12, 21. https:\/\/doi.org\/10.1038\/s41413-024-00362-4 (2024).","journal-title":"Bone Res."},{"key":"19835_CR6","doi-asserted-by":"publisher","first-page":"1427060","DOI":"10.3389\/froh.2024.1427060","volume":"5","author":"D Oryniak","year":"2024","unstructured":"Oryniak, D., Brown, M., Cholakis, L., Elgazzar, R. & Case Report Development of medication-related osteonecrosis of the jaw in a patient on long-term Infliximab therapy. Front. Oral Health. 5, 1427060. https:\/\/doi.org\/10.3389\/froh.2024.1427060 (2024).","journal-title":"Front. Oral Health"},{"key":"19835_CR7","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1007\/s00198-023-06863-y","volume":"34","author":"J Everts-Graber","year":"2023","unstructured":"Everts-Graber, J. et al. Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study. Osteoporos. Int. 34, 1961\u20131973. https:\/\/doi.org\/10.1007\/s00198-023-06863-y (2023).","journal-title":"Osteoporos. Int."},{"key":"19835_CR8","doi-asserted-by":"publisher","unstructured":"Wajda, B. G. et al. Denosumab vs. Zoledronic acid for metastatic bone disease: A comprehensive systematic review and Meta-Analysis of randomized controlled trials. Cancers 17 https:\/\/doi.org\/10.3390\/cancers17030388 (2025).","DOI":"10.3390\/cancers17030388"},{"key":"19835_CR9","doi-asserted-by":"publisher","unstructured":"Kang, T., Park, S. Y., Lee, S. H., Park, J. H. & Suh, S. W. Comparison of denosumab and Zoledronic acid in postmenopausal women with osteoporosis: bone mineral density (BMD) and trabecular bone score (TBS). J. Korean Med. Sci. 37 https:\/\/doi.org\/10.3346\/jkms.2022.37.e68 (2022).","DOI":"10.3346\/jkms.2022.37.e68"},{"key":"19835_CR10","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1007\/s11701-023-01700-0","volume":"17","author":"X Wang","year":"2023","unstructured":"Wang, X., Zhu, Y. H. & Zhu, Q. S. Efficacy and safety of robot-assisted versus fluoroscopy-assisted PKP or PVP for osteoporotic vertebral compression fractures: a systematic review and meta-analysis. J. Robot Surg. 17, 2597\u20132610. https:\/\/doi.org\/10.1007\/s11701-023-01700-0 (2023).","journal-title":"J. Robot Surg."},{"key":"19835_CR11","doi-asserted-by":"publisher","first-page":"E1333","DOI":"10.1503\/cmaj.221647","volume":"195","author":"SN Morin","year":"2023","unstructured":"Morin, S. N. et al. Clinical practice guideline for management of osteoporosis and fracture prevention in canada: 2023 update. Can. Med. Assoc. J. 195, E1333\u2013E1348. https:\/\/doi.org\/10.1503\/cmaj.221647 (2023).","journal-title":"Can. Med. Assoc. J."},{"key":"19835_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13018-022-03038-z","volume":"17","author":"CQ Dai","year":"2022","unstructured":"Dai, C. Q., Liang, G., Zhang, Y. S., Dong, Y. & Zhou, X. D. Risk factors of vertebral re-fracture after PVP or PKP for osteoporotic vertebral compression fractures, especially in Eastern asia: a systematic review and meta-analysis. J. Orthop. Surg. Res. 17, 11. https:\/\/doi.org\/10.1186\/s13018-022-03038-z (2022).","journal-title":"J. Orthop. Surg. Res."},{"key":"19835_CR13","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1111\/os.14087","volume":"16","author":"J Zou","year":"2024","unstructured":"Zou, J. et al. A Real-world study of denosumab for reducing refracture risk after percutaneous vertebral augmentation. Orthop. Surg. 16, 1849\u20131860. https:\/\/doi.org\/10.1111\/os.14087 (2024).","journal-title":"Orthop. Surg."},{"key":"19835_CR14","doi-asserted-by":"publisher","unstructured":"Anastasilakis, A. D. et al. Similarities and differences in the management of patients with osteoporotic vertebral fractures and those with Rebound-Associated vertebral fractures following discontinuation of denosumab. J. Clin. Med. 12 https:\/\/doi.org\/10.3390\/jcm12185874 (2023).","DOI":"10.3390\/jcm12185874"},{"key":"19835_CR15","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","volume":"32","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis, A. D. et al. Clinical features of 24 patients with Rebound-Associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J. Bone Min. Res. 32, 1291\u20131296. https:\/\/doi.org\/10.1002\/jbmr.3110 (2017).","journal-title":"J. Bone Min. Res."},{"key":"19835_CR16","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.clinthera.2020.04.011","volume":"42","author":"FC Kao","year":"2020","unstructured":"Kao, F. C., Hsu, Y. C., Chen, T. S., Tu, Y. K. & Liu, P. H. Effects of injected antiosteoporotic medication versus oral bisphosphonates on rates of repeated vertebroplasty or kyphoplasty. Clin. Ther. 42, 1087\u20131098e1082. https:\/\/doi.org\/10.1016\/j.clinthera.2020.04.011 (2020).","journal-title":"Clin. Ther."},{"key":"19835_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1055\/a-1368-4218","volume":"53","author":"L Tripto-Shkolnik","year":"2021","unstructured":"Tripto-Shkolnik, L., Liel, Y., Yekutiel, N. & Goldshtein, I. Long-Term Follow-Up of denosumab discontinuers with multiple vertebral fractures in the Real-World: A case series. Horm. Metab. Res. 53, 185\u2013190. https:\/\/doi.org\/10.1055\/a-1368-4218 (2021).","journal-title":"Horm. Metab. Res."},{"key":"19835_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jbspin.2019.07.010","volume":"87","author":"J Dupont","year":"2020","unstructured":"Dupont, J. et al. Rebound-associated vertebral fractures after stopping denosumab: report of four cases. Joint Bone Spine. 87, 171\u2013173. https:\/\/doi.org\/10.1016\/j.jbspin.2019.07.010 (2020).","journal-title":"Joint Bone Spine"},{"key":"19835_CR19","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/jc.2016-3170","volume":"102","author":"O Lamy","year":"2017","unstructured":"Lamy, O., Gonzalez-Rodriguez, E., Stoll, D., Hans, D. & Aubry-Rozier, B. Severe Rebound-Associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J. Clin. Endocrinol. Metab. 102, 354\u2013358. https:\/\/doi.org\/10.1210\/jc.2016-3170 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"19835_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/medicina60081314","volume":"60","author":"BT Kwon","year":"2024","unstructured":"Kwon, B. T., Ham, D. W., Park, S. M., Kim, H. J. & Yeom, J. S. Impact of teriparatide and denosumab on clinical and radiographic outcomes in osteoporotic vertebral compression fractures. Med. Lith. 60, 10. https:\/\/doi.org\/10.3390\/medicina60081314 (2024).","journal-title":"Med. Lith."},{"key":"19835_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jdiacomp.2024.108718","volume":"38","author":"JWJ Lasschuit","year":"2024","unstructured":"Lasschuit, J. W. J., Center, J. R., Greenfield, J. R. & Tonks, K. T. T. Effect of denosumab on inflammation and bone health in active Charcot foot: A phase II randomised controlled trial. J. Diabetes Complications. 38, 9. https:\/\/doi.org\/10.1016\/j.jdiacomp.2024.108718 (2024).","journal-title":"J. Diabetes Complications"},{"key":"19835_CR22","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron, R., Ferrari, S. & Russell, R. G. G. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48, 677\u2013692. https:\/\/doi.org\/10.1016\/j.bone.2010.11.020 (2011).","journal-title":"Bone"},{"key":"19835_CR23","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/jbmr.3376","volume":"33","author":"GQ Cai","year":"2018","unstructured":"Cai, G. Q. et al. Effect of Zoledronic acid and denosumab in patients with low back pain and modic change: A Proof-of-Principle trial. J. Bone Min. Res. 33, 773\u2013782. https:\/\/doi.org\/10.1002\/jbmr.3376 (2018).","journal-title":"J. Bone Min. Res."},{"key":"19835_CR24","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00198-015-3331-7","volume":"27","author":"V Hegde","year":"2016","unstructured":"Hegde, V., Jo, J. E., Andreopoulou, P. & Lane, J. M. Effect of osteoporosis medications on fracture healing. Osteoporos. Int. 27, 861\u2013871. https:\/\/doi.org\/10.1007\/s00198-015-3331-7 (2016).","journal-title":"Osteoporos. Int."},{"key":"19835_CR25","doi-asserted-by":"publisher","first-page":"e2159","DOI":"10.1210\/clinem\/dgae207","volume":"109","author":"LC Hofbauer","year":"2024","unstructured":"Hofbauer, L. C. & Rauner, M. Denosumab-Protection for bone and beyond?? Clin. Endocrinol. Metab. 109, e2159\u2013e2160. https:\/\/doi.org\/10.1210\/clinem\/dgae207 (2024).","journal-title":"Clin. Endocrinol. Metab."},{"key":"19835_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/jbmr.4434","volume":"37","author":"DM Black","year":"2022","unstructured":"Black, D. M. et al. The interaction of Acute-Phase reaction and efficacy for osteoporosis after Zoledronic acid: HORIZON pivotal fracture trial. J. Bone Min. Res. 37, 21\u201328. https:\/\/doi.org\/10.1002\/jbmr.4434 (2022).","journal-title":"J. Bone Min. Res."},{"key":"19835_CR27","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s00198-023-06803-w","volume":"34","author":"K Lu","year":"2023","unstructured":"Lu, K. et al. The impact of acute-phase reaction on mortality and re-fracture after Zoledronic acid in hospitalized elderly osteoporotic fracture patients. Osteoporos. Int. 34, 1613\u20131623. https:\/\/doi.org\/10.1007\/s00198-023-06803-w (2023).","journal-title":"Osteoporos. Int."},{"key":"19835_CR28","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1177\/0960327119829527","volume":"38","author":"Z Lan","year":"2019","unstructured":"Lan, Z., Chai, K., Jiang, Y. & Liu, X. Characterization of urinary biomarkers and their relevant mechanisms of zoledronate-induced nephrotoxicity using rats and HK-2 cells. Hum. Exp. Toxicol. 38, 598\u2013609. https:\/\/doi.org\/10.1177\/0960327119829527 (2019).","journal-title":"Hum. Exp. Toxicol."},{"key":"19835_CR29","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1001\/jamaoncol.2023.6520","volume":"10","author":"SH Zhang","year":"2024","unstructured":"Zhang, S. H. et al. Efficacy, safety, and population pharmacokinetics of MW032 compared with denosumab for solid Tumor-Related bone metastases. JAMA Oncol. 10, 448\u2013455. https:\/\/doi.org\/10.1001\/jamaoncol.2023.6520 (2024).","journal-title":"JAMA Oncol."},{"key":"19835_CR30","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings, S. R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl. J. Med. 361, 756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493 (2009).","journal-title":"N Engl. J. Med."},{"key":"19835_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00198-018-4687-2","volume":"30","author":"DL Kendler","year":"2019","unstructured":"Kendler, D. L. et al. The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM extension studies. Osteoporos. Int. 30, 71\u201378. https:\/\/doi.org\/10.1007\/s00198-018-4687-2 (2019).","journal-title":"Osteoporos. Int."},{"key":"19835_CR32","doi-asserted-by":"publisher","unstructured":"Ramchand, S. K. et al. The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial. Osteoporos. Int. 9 https:\/\/doi.org\/10.1007\/s00198-023-06932-2 (2023).","DOI":"10.1007\/s00198-023-06932-2"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19835-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19835-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19835-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:02:45Z","timestamp":1763942565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19835-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["19835"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-19835-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"16 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of the First Affiliated Hospital of Guangzhou University of Chinese Medicine. The authors confirm that the study was performed in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"40676"}}